Wegovy has a list price of $1,349 per month before any discounts, but most people pay significantly less through a combination of insurance coverage, manufacturer programs, and newer subscription pricing models. Depending on your situation, you could pay as little as $25 a month or even get it free. The key is knowing which cost-reduction paths apply to you and stacking them when possible.
The Novo Nordisk Savings Card
If you have commercial insurance that covers Wegovy, the manufacturer’s savings card is the fastest way to cut your copay. It brings your out-of-pocket cost down to as little as $25 per month, with a maximum savings of $100 per one-month fill, $200 per two-month fill, or $300 per three-month fill. You can sign up through the NovoCare website, and most pharmacies process it like a secondary insurance card at the counter.
This card does not work with government insurance programs like Medicare, Medicaid, or Tricare. It also won’t help if your plan explicitly excludes Wegovy. But if your insurer covers the drug and you’re still facing a high copay, this card is the single easiest move to make.
Getting Your Insurance to Cover It
Most commercial plans that cover Wegovy require prior authorization, which means your doctor needs to submit paperwork proving you meet specific criteria. The standard threshold follows the FDA label: a BMI over 30, or a BMI over 27 with at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol. A small number of plans set the bar higher than the label, requiring a BMI above 30 regardless of other conditions.
Beyond BMI, many plans add extra hoops. About two-thirds of commercial plans require you to be following a reduced-calorie diet, increasing physical activity, or participating in some form of lifestyle modification. Roughly half require enrollment in a behavioral modification program before they’ll approve the prescription. And nearly all plans require you to demonstrate at least 4% to 5% weight loss from your baseline to continue coverage at renewal.
If your plan denies coverage, ask your doctor to file an appeal. Having documentation of failed diet attempts, a history of weight-related health problems, or participation in a structured weight management program strengthens your case. The 2024 FDA approval of Wegovy for reducing cardiovascular risk in people with obesity or overweight combined with heart disease has also pushed more insurers to add it to their formularies, so a plan that rejected you a year ago may cover you now.
Novo Nordisk’s Patient Assistance Program
If you’re uninsured, Novo Nordisk offers Wegovy at no cost through its Patient Assistance Program (PAP) for qualifying households. For most Novo Nordisk medications, your total household income must be at or below 400% of the federal poverty level. For a single person in 2025, that’s roughly $62,000 a year; for a family of four, around $127,000.
You’ll need to provide proof of income and, if applicable, a Medicaid denial letter showing you don’t qualify for state coverage. Medicare beneficiaries with household income below 150% of the federal poverty level can also qualify, but they must first apply for and be denied Part D Extra Help (the Low Income Subsidy) and submit that denial letter with their application. The application process runs through NovoCare and your prescriber’s office typically helps submit the paperwork.
Subscription Pricing Through Telehealth
Novo Nordisk introduced a subscription pricing model for Wegovy through telehealth platforms like Ro, WeightWatchers, and LifeMD. For injectable Wegovy, monthly costs range from $329 on a three-month plan down to $249 on a twelve-month plan. Oral Wegovy (the tablet form) costs $289 per month on a three-month plan and also drops to $249 on a twelve-month commitment.
GoodRx launched its own telehealth weight loss program offering the two lowest doses of oral semaglutide at $149 per month through April 2026, with higher doses priced at $299 monthly. These subscription prices include the medication itself and typically bundle in clinical consultations, so you’re not paying a separate prescriber fee on top of the drug cost. Compared to the $1,349 list price, this represents savings of 75% to 89% even without insurance.
Pharmacy Discount Coupons
If you’re paying cash, always check GoodRx, RxSaver, or similar coupon aggregators before filling your prescription. GoodRx currently advertises Wegovy for as low as $149, which it lists as 91% off the average retail price of around $1,643. Prices vary by pharmacy location, so compare several nearby options. Costco and independent pharmacies sometimes offer lower base prices than chain drugstores. These coupons can’t be combined with insurance, but for uninsured patients who don’t qualify for the PAP, they can dramatically cut costs.
Medicare Coverage: Limited but Expanding
Medicare Part D currently does not cover Wegovy when it’s prescribed solely for weight loss. However, since the March 2024 FDA approval for cardiovascular risk reduction, Part D does cover Wegovy for enrollees who have obesity or overweight combined with established cardiovascular disease. If you have both conditions, your doctor can prescribe it under that indication.
A proposed federal rule would reinterpret the longstanding statutory exclusion of “weight loss drugs” under Part D so that it no longer applies to medications used to treat obesity as a disease. If finalized, this would open Wegovy coverage to a much larger group of Medicare beneficiaries. That change has not taken effect yet, but it signals the direction policy is moving.
Why Compounded Semaglutide Is Risky
Compounding pharmacies have sold cheaper versions of semaglutide, sometimes for a fraction of the brand-name price. The FDA has raised serious concerns about these products. As of July 2025, the agency has received 605 adverse event reports linked to compounded semaglutide, including hospitalizations from dosing errors where patients or even healthcare providers miscalculated injectable doses.
Some compounded products use salt forms of semaglutide (like semaglutide sodium or semaglutide acetate) that are chemically different from the active ingredient in approved Wegovy. The FDA says it has no data confirming these salts behave the same way in the body. The agency has also found fraudulent products with fake pharmacy names on the labels and reports of medications arriving warm due to inadequate cold-chain shipping. The FDA’s position is clear: compounded drugs should only be used when an FDA-approved version can’t meet a patient’s medical needs.
Generic Semaglutide on the Horizon
Novo Nordisk’s core U.S. patent on semaglutide is set to expire in 2032. In October 2024, the company settled patent disputes with several major generic manufacturers, including Mylan (Viatris), Sun Pharmaceutical, Dr. Reddy’s, and Apotex. The settlement terms are confidential but likely include agreed-upon dates for generic market entry and possible royalty arrangements. Generic competition typically drives prices down 80% or more, but that relief is still years away.
In the meantime, the most effective strategy is layering multiple savings tools. Start with your insurance coverage and a prior authorization request, add the manufacturer savings card if you have commercial coverage, explore telehealth subscription pricing if you’re paying out of pocket, and check the Patient Assistance Program if your income qualifies. The difference between the list price and what you actually pay can be over $1,000 a month.